{"id":1987,"date":"2026-09-12T13:30:00","date_gmt":"2026-09-12T04:30:00","guid":{"rendered":"https:\/\/onepress.co.kr\/index.php\/briefing\/2026-09-12-esophagus-treatment-selection-en\/"},"modified":"2026-09-12T13:30:00","modified_gmt":"2026-09-12T04:30:00","slug":"2026-09-12-esophagus-treatment-selection-en","status":"publish","type":"briefing","link":"https:\/\/onepress.co.kr\/index.php\/briefing\/2026-09-12-esophagus-treatment-selection-en\/","title":{"rendered":"Weeks of cancer therapy reshaped competition among mutant cells in normal oesophagus"},"content":{"rendered":"

2026-09-12 13:30 KST<\/strong><\/p>\n

Normal oesophageal lining removed at surgery showed that chemotherapy and chemoradiotherapy favoured different mutant cell populations. Five to eight weeks of treatment could alter competition built over decades.<\/p>\n

The central result is selection among pre-existing clones, not proof that treatment generated all mutations. Most somatic mutations do not become cancer, and this study cannot predict an individual\u2019s recurrence.<\/p>\n

Who was compared?<\/h2>\n

Seventy patients were split among no pretreatment (21), ECX (17), EOX (14), FLOT (7) and CROSS chemoradiotherapy (11). These were not paired before-and-after samples.<\/p>\n

What changed?<\/h2>\n

TP53 and PPM1D clones expanded in CROSS, while RAC1, NFE2L2 and MTOR selection appeared in FLOT, consistent with treatment-specific resilience.<\/p>\n

\"Weeks
This AI-generated image explains the topic; it is not a photograph of the actual site, experiment, animal or fossil.<\/figcaption><\/figure>\n

New mutations?<\/h2>\n

The team did not find clear chemotherapy mutational signatures despite fitness changes, underscoring creation versus selection.<\/p>\n

Limits<\/h2>\n

The five groups were small, 324 cancer-related genes were targeted, and only post-treatment surgical tissue was sequenced.<\/p>\n

Next<\/h2>\n

A pilot is sampling cheek cells, blood and urine before and after other cancer treatments. The findings guide research, not treatment cessation.<\/p>\n

Primary source and independent checks<\/h2>\n

Nature Genetics \uc6d0 \ub17c\ubb38<\/a><\/p>\n

Wellcome Sanger Institute \uc5f0\uad6c \ubc1c\ud45c<\/a><\/p>\n

EGA \uc5f0\uad6c \ub370\uc774\ud130 \uc124\uba85<\/a><\/p>\n

Read in other languages<\/h2>\n

\ud55c\uad6d\uc5b4<\/a> \u00b7 English<\/a> \u00b7 Espa\u00f1ol<\/a> \u00b7 \u65e5\u672c\u8a9e<\/a> \u00b7 Ti\u1ebfng Vi\u1ec7t<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Normal tissue from 70 patients showed treatment-specific expansion of pre-existing mutant clones. It does not mean therapy created every mutation or that those cells will become cancer.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":[],"class_list":["post-1987","briefing","type-briefing","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/briefing\/1987","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/briefing"}],"about":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/types\/briefing"}],"wp:attachment":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/media?parent=1987"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}